Cisen Pharmaceutical
ISIN CNE100002VG4
|WKN A3DC4R
Overview
Description
Cisen Pharmaceutical Ltd. engages in the manufacture and distribution of comprehensive chemical and pharmaceutical products. It also develops and distributes voglibose capsules, cycloclenbuterol hydrochloride tablets, glycerol fructose & sodium chloride injection, dexmedetomidine hydrochloride injection and other related drugs. The company was founded on November 6, 1998 and is headquartered in Jining, China.
Healthcare Biopharmaceuticals Other Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 937.76 m |
| EPS, EUR | 0.15 |
| P/B ratio | 1.23 |
| P/E ratio | 13.76 |
| Dividend yield | 2.08% |
Income statement (2023)
| Revenue, EUR | 575.40 m |
| Net income, EUR | 68.13 m |
| Profit margin | 11.84% |
What ETF is Cisen Pharmaceutical in?
There is 1 ETF which contains Cisen Pharmaceutical.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| VanEck New China ESG UCITS ETF A | 1.19% | Equity China Growth | 99 | 0.60% | 5 | -12.84% | A3CR8S | IE0000H445G8 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.